Pathology: mNSCLC - L2 - PDL1 positive;
mNSCLC - L2 - PDL1 positive | ||||||||
OAK (PDL1 TC 1/2/3), 2016 | JAVELIN Lung 200 (PDL1 >1%), 2018 | ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 | KEYNOTE-010 (P:10 mg/kg), 2016 | KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016 | KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016 | KEYNOTE-010 (P: 2mg/kg), 2016 | ||
pembrolizumab (10mg/kg) | 2 | T1 | T1 | |||||
pembrolizumab (2mg/kg) | 2 | T1 | T1 | |||||
durvalumab alone | 1 | T1 | ||||||
avelumab alone | 1 | T1 | ||||||
atezolizumab alone | 1 | T1 | ||||||
Standard of Care (SoC) | 0 | T0 | ||||||
docetaxel | 0 | T0 | T0 | T0 | T0 | T0 | T0 |